Take the Diabetes Health Pump Survey
See What's Inside
Read this FREE issue now
For healthcare professionals only
  • 12 Tips for Traveling With Diabetes
See the entire table of contents here!

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter
Latest
Popular
Top Rated
Diabetes Archives
Print | Email | Share | Comments (4)

New Data From Phase 3 Trial Says Liraglutide Is More Effective Than Exenatide For Type 2s

Oct 27, 2008

This press release is an announcement submitted by Novo Nordisk, and was not written by Diabetes Health.

Liraglutide is under development by Novo Nordisk. It's a member of a new class of diabetes medications called GLP-1 analogues.

Novo Nordisk recently announced results from its LEAD 6 study showing that once daily liraglutide was significantly more effective at improving blood glucose control (as measured by A1c) than exenatide, a GLP-1 mimetic administered twice daily.

Liraglutide works by stimulating the release of insulin and inhibiting the release of glucagon from the liver after meals only if blood glucose levels are elevated. 

"In this study, reduction in blood glucose was greater with liraglutide than with exenatide" said Lawrence Blonde, MD, Director of the Ochsner Diabetes Clinical Research Unit in the Department of Endocrinology, Diabetes, and Metabolism at the Oxford Center in New Orleans. "Patients treated with once daily liraglutide achieved better blood glucose control and also had less minor hypoglycemia than those treated with exenatide." 

The 26-week study included 464 people with type 2 diabetes who were randomized to treatment with either liraglutide, 1.8 mg once daily, or exenatide, 10 µg twice daily, both as an add-on to their existing treatment consisting of metformin and/or a sulfonylurea. 

Nausea was the most common side effect for both treatments and was reported at a level of 25.5% in the liraglutide group and 28% in exenatide group (percent of all study participants reporting nausea at least once). However, according to the Novo Nordisk press release, in the liraglutide group, the percentage of patients reporting nausea fell each week fell to just 3% after 26 weeks. In the exenatide group, reports of nausea remained above 10% for more than 20 weeks. 

Other common gastrointestinal-related adverse events with liraglutide were diarrhea, vomiting, and dyspepsia.  

Weight loss with liraglutide is attributed to the fact that it slows gastric emptying and leads to increased satiety after meals. Liraglutide is naturally broken down in the body and does not require renal excretion. 

Source: Novo Nordisk


Categories: A1c Test, Blood Glucose, Diabetes, Diabetes, Insulin, Low Blood Sugar, Medications, Medications Research, Novo Nordisk, Type 2 Issues



You May Also Be Interested In...


Comments

Posted by dandbcollier on 30 October 2008

Where are the numbers showing that liraglutide lowered A1C more than exenatide?

Posted by Anonymous on 30 October 2008

Sounds like another "me too" product from novo nordisk, just like their Novolog. Byetta is phenomenal, and as soon as the once-weekly comes out (probably very shortly after liraglutide), it will be a no-brainer anyway!

Posted by Anonymous on 8 December 2008

They didn't say if it was injected like Byetta or if it is a pill.

Posted by Anonymous on 29 December 2008

I believe that liraglutide is administered via subcutaneous injection.


Add your comments about this article below. You can add comments as a registered user or anonymously. If you choose to post anonymously your comments will be sent to our moderator for approval before they appear on this page. If you choose to post as a registered user your comments will appear instantly.

When voicing your views via the comment feature, please respect the Diabetes Health community by refraining from comments that could be considered offensive to other people. Diabetes Health reserves the right to remove comments when necessary to maintain the cordial voice of the diabetes community.

For your privacy and protection, we ask that you do not include personal details such as address or telephone number in any comments posted.

Don't have your Diabetes Health Username? Register now and add your comments to all our content.

Have Your Say...


Username: Password:
Comment:
©1991-2014 Diabetes Health | Home | Privacy | Press | Advertising | Help | Contact Us | Donate | Sitemap

Diabetes Health Medical Disclaimer

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.